Maze Therapeutics Inc Reports Q4 Operating Loss of $38.059 Million, Exceeding IBES Estimate of $36 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 25 2026
0mins
Should l Buy MAZE?
Source: moomoo
- Financial Performance: Maze Therapeutics reported Q4 income from operations of USD 38.059 million.
- Comparison with Estimates: This figure exceeds the estimated income of USD 36 million.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MAZE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MAZE
Wall Street analysts forecast MAZE stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 29.050
Low
46.00
Averages
52.00
High
60.00
Current: 29.050
Low
46.00
Averages
52.00
High
60.00
About MAZE
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Maze Therapeutics Executive Sells Shares Amid Declining Stock Price
- Executive Stock Sale: Harold Bernstein, R&D President of Maze Therapeutics, sold 15,000 shares of common stock on April 1, 2026, for approximately $442,000, marking a complete exit from his direct holdings and indicating a strategic withdrawal from direct investment in the company.
- Options Exercise Context: The transaction was executed through the exercise of options, and Bernstein retains 237,407 outstanding stock options, suggesting he still has the potential to acquire shares in the future despite having no direct holdings.
- Market Reaction Analysis: Maze Therapeutics' stock price surged 208.05% over the past year, but after reaching a 52-week high of $53.65, the stock experienced a decline as investors began to cash in, which may correlate with Bernstein's sale.
- Investment Risk Advisory: While Bernstein's sale is not necessarily a negative signal as it was conducted under a Rule 10b5-1 trading plan, the company has yet to generate revenue and reported a net loss of $131.1 million in 2025, prompting investors to carefully assess the future approval prospects of its kidney drug, MZE829.
See More
Chief Medical Officer Sells All Shares
- Share Sale Details: Chief Medical Officer Harold Bernstein sold 15,000 shares of the company on April 1, 2026, for approximately $442,000 at around $29.46 per share, marking a complete exit from his direct Common Stock holdings.
- Transaction Context: The sale was executed through the exercise of options and immediate disposition, with Bernstein utilizing a Rule 10b5-1 trading plan adopted in September 2025 to avoid insider trading accusations, although he retains over 237,000 stock options.
- Market Reaction and Price Fluctuation: Bernstein's sale occurred during a decline in Maze Therapeutics' stock price, which had reached a 52-week high of $53.65 in March due to positive clinical trial data, but investors began cashing in on high valuations, leading to a price drop.
- Company Financial Status: Maze Therapeutics ended 2025 with a net loss of $131.1 million and currently does not generate revenue, indicating high investment risk, as investors must have confidence in the potential federal approval of its lead kidney drug, MZE829.
See More
Biotech Landscape Update: Regulatory Approvals and Mergers
- Anavex Drug Withdrawal: Anavex Life Sciences Corp. (AVXL) withdrew its EU marketing application for Alzheimer's drug Blarcamesine after the EMA's CHMP indicated it could not issue a positive opinion, marking a significant setback for the company's lead candidate despite continued support from patient groups.
- Quoin FDA Alignment: Quoin Pharmaceuticals Ltd. (QNRX) received positive feedback from the FDA confirming that a single Phase 3 trial may suffice for U.S. approval of QRX003 for Netherton Syndrome, with plans to initiate Phase 3 in 2026 and potentially file an NDA in 2027.
- Corcept Drug Approval: Corcept Therapeutics Inc. (CORT) secured FDA approval for Lifyorli combined with nab-paclitaxel to treat platinum-resistant ovarian cancer, based on Phase 3 ROSELLA trial results involving 381 patients, marking the first FDA-approved selective glucocorticoid receptor antagonist.
- Merck Acquires Terns: Merck (MRK) announced a definitive agreement to acquire Terns Pharmaceuticals for $53.00 per share, totaling approximately $6.7 billion, which is expected to enhance Merck's presence in hematology, with the transaction anticipated to close in Q2 2026.
See More
Investigation into Potential Claims for Maze Therapeutics Investors
- Clinical Trial Results: On March 25, 2026, Maze Therapeutics announced topline results from its Phase 2 HORIZON trial, showing that MZE829 achieved a mean reduction of approximately 35.6% in urine albumin-to-creatinine ratio (uACR) at Week 12, with about 50% of patients experiencing over a 30% reduction, which the company characterized as 'clinically meaningful'.
- Stock Price Plunge: Following the announcement of these clinical results, Maze's stock price declined by approximately 33% on March 25, 2026, indicating a negative market reaction that could lead to significant losses for investors.
- Legal Investigation Initiated: Johnson Fistel, PLLP is investigating whether Maze's executives complied with federal securities laws, particularly regarding potential improper disclosures following the stock price drop, aiming to seek compensation for affected investors.
- Investor Rights Protection: Johnson Fistel, a nationally recognized shareholder rights law firm, was ranked among the Top 10 Plaintiff Law Firms in 2024, successfully recovering approximately $90.725 million for clients, demonstrating its effectiveness in advocating for investor rights.
See More
Maze Therapeutics Executive Exercises Stock Options Amid Market Volatility
- Executive Stock Transaction: Harold Bernstein, the CMO of Maze Therapeutics, exercised 15,000 stock options and immediately sold the shares for approximately $736,000, indicating a strategy of utilizing options for liquidity rather than reducing existing stock positions.
- Market Reaction: Despite Maze Therapeutics reporting positive topline data from the Phase 2 HORIZON Trial of MZE829, the stock plummeted 33% on Wednesday, reflecting market sensitivity to executive stock sales and potential liquidity events.
- Significant Clinical Progress: MZE829 demonstrated a 35.6% reduction in proteinuria in clinical trials, with half of the patients achieving at least a 30% reduction, indicating potential for delaying disease progression and strong efficacy in certain subgroups.
- Long-term Investment Outlook: While the stock experiences short-term volatility, the progress in Maze Therapeutics' pipeline and its focus on genetically validated small molecule drugs provide a solid foundation for future commercialization, suggesting a favorable outlook for long-term investors.
See More
Maze Therapeutics Shares Plunge 37% Despite Positive Trial Data
- Clinical Trial Data: Maze Therapeutics reported 12-week data from its HORIZON study showing that MZE829 led to a clinically meaningful decline in proteinuria, with an average uACR reduction of 35.6% among 12 patients, indicating potential efficacy in treating APOL1-mediated kidney disease.
- Safety Analysis: The safety analysis involving 15 patients indicated that MZE829 was well tolerated, with common treatment-related adverse events including headache and diarrhea, and no serious adverse events reported, highlighting the drug's safety profile.
- Market Reaction: Despite the encouraging initial data, Maze Therapeutics' stock plummeted approximately 37%, reflecting market concerns about the company's future prospects, possibly linked to investor interpretation of the clinical trial results.
- Financial Position: Ahead of the trial readout, Maze Therapeutics reported its Q4 2025 financial results, indicating a cash runway extending into 2028, which underscores the company's financial stability amidst ongoing clinical developments.
See More
Maze Therapeutics Executive Sells Shares Amid Declining Stock Price
- Executive Stock Sale: Harold Bernstein, R&D President of Maze Therapeutics, sold 15,000 shares of common stock on April 1, 2026, for approximately $442,000, marking a complete exit from his direct holdings and indicating a strategic withdrawal from direct investment in the company.
- Options Exercise Context: The transaction was executed through the exercise of options, and Bernstein retains 237,407 outstanding stock options, suggesting he still has the potential to acquire shares in the future despite having no direct holdings.
- Market Reaction Analysis: Maze Therapeutics' stock price surged 208.05% over the past year, but after reaching a 52-week high of $53.65, the stock experienced a decline as investors began to cash in, which may correlate with Bernstein's sale.
- Investment Risk Advisory: While Bernstein's sale is not necessarily a negative signal as it was conducted under a Rule 10b5-1 trading plan, the company has yet to generate revenue and reported a net loss of $131.1 million in 2025, prompting investors to carefully assess the future approval prospects of its kidney drug, MZE829.
See More
Chief Medical Officer Sells All Shares
- Share Sale Details: Chief Medical Officer Harold Bernstein sold 15,000 shares of the company on April 1, 2026, for approximately $442,000 at around $29.46 per share, marking a complete exit from his direct Common Stock holdings.
- Transaction Context: The sale was executed through the exercise of options and immediate disposition, with Bernstein utilizing a Rule 10b5-1 trading plan adopted in September 2025 to avoid insider trading accusations, although he retains over 237,000 stock options.
- Market Reaction and Price Fluctuation: Bernstein's sale occurred during a decline in Maze Therapeutics' stock price, which had reached a 52-week high of $53.65 in March due to positive clinical trial data, but investors began cashing in on high valuations, leading to a price drop.
- Company Financial Status: Maze Therapeutics ended 2025 with a net loss of $131.1 million and currently does not generate revenue, indicating high investment risk, as investors must have confidence in the potential federal approval of its lead kidney drug, MZE829.
See More
Biotech Landscape Update: Regulatory Approvals and Mergers
- Anavex Drug Withdrawal: Anavex Life Sciences Corp. (AVXL) withdrew its EU marketing application for Alzheimer's drug Blarcamesine after the EMA's CHMP indicated it could not issue a positive opinion, marking a significant setback for the company's lead candidate despite continued support from patient groups.
- Quoin FDA Alignment: Quoin Pharmaceuticals Ltd. (QNRX) received positive feedback from the FDA confirming that a single Phase 3 trial may suffice for U.S. approval of QRX003 for Netherton Syndrome, with plans to initiate Phase 3 in 2026 and potentially file an NDA in 2027.
- Corcept Drug Approval: Corcept Therapeutics Inc. (CORT) secured FDA approval for Lifyorli combined with nab-paclitaxel to treat platinum-resistant ovarian cancer, based on Phase 3 ROSELLA trial results involving 381 patients, marking the first FDA-approved selective glucocorticoid receptor antagonist.
- Merck Acquires Terns: Merck (MRK) announced a definitive agreement to acquire Terns Pharmaceuticals for $53.00 per share, totaling approximately $6.7 billion, which is expected to enhance Merck's presence in hematology, with the transaction anticipated to close in Q2 2026.
See More
Investigation into Potential Claims for Maze Therapeutics Investors
- Clinical Trial Results: On March 25, 2026, Maze Therapeutics announced topline results from its Phase 2 HORIZON trial, showing that MZE829 achieved a mean reduction of approximately 35.6% in urine albumin-to-creatinine ratio (uACR) at Week 12, with about 50% of patients experiencing over a 30% reduction, which the company characterized as 'clinically meaningful'.
- Stock Price Plunge: Following the announcement of these clinical results, Maze's stock price declined by approximately 33% on March 25, 2026, indicating a negative market reaction that could lead to significant losses for investors.
- Legal Investigation Initiated: Johnson Fistel, PLLP is investigating whether Maze's executives complied with federal securities laws, particularly regarding potential improper disclosures following the stock price drop, aiming to seek compensation for affected investors.
- Investor Rights Protection: Johnson Fistel, a nationally recognized shareholder rights law firm, was ranked among the Top 10 Plaintiff Law Firms in 2024, successfully recovering approximately $90.725 million for clients, demonstrating its effectiveness in advocating for investor rights.
See More
Maze Therapeutics Executive Exercises Stock Options Amid Market Volatility
- Executive Stock Transaction: Harold Bernstein, the CMO of Maze Therapeutics, exercised 15,000 stock options and immediately sold the shares for approximately $736,000, indicating a strategy of utilizing options for liquidity rather than reducing existing stock positions.
- Market Reaction: Despite Maze Therapeutics reporting positive topline data from the Phase 2 HORIZON Trial of MZE829, the stock plummeted 33% on Wednesday, reflecting market sensitivity to executive stock sales and potential liquidity events.
- Significant Clinical Progress: MZE829 demonstrated a 35.6% reduction in proteinuria in clinical trials, with half of the patients achieving at least a 30% reduction, indicating potential for delaying disease progression and strong efficacy in certain subgroups.
- Long-term Investment Outlook: While the stock experiences short-term volatility, the progress in Maze Therapeutics' pipeline and its focus on genetically validated small molecule drugs provide a solid foundation for future commercialization, suggesting a favorable outlook for long-term investors.
See More
Maze Therapeutics Shares Plunge 37% Despite Positive Trial Data
- Clinical Trial Data: Maze Therapeutics reported 12-week data from its HORIZON study showing that MZE829 led to a clinically meaningful decline in proteinuria, with an average uACR reduction of 35.6% among 12 patients, indicating potential efficacy in treating APOL1-mediated kidney disease.
- Safety Analysis: The safety analysis involving 15 patients indicated that MZE829 was well tolerated, with common treatment-related adverse events including headache and diarrhea, and no serious adverse events reported, highlighting the drug's safety profile.
- Market Reaction: Despite the encouraging initial data, Maze Therapeutics' stock plummeted approximately 37%, reflecting market concerns about the company's future prospects, possibly linked to investor interpretation of the clinical trial results.
- Financial Position: Ahead of the trial readout, Maze Therapeutics reported its Q4 2025 financial results, indicating a cash runway extending into 2028, which underscores the company's financial stability amidst ongoing clinical developments.
See More
